<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39150063</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1469-896X</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Protein science : a publication of the Protein Society</Title><ISOAbbreviation>Protein Sci</ISOAbbreviation></Journal><ArticleTitle>Profiling of coronaviral M<sup>pro</sup> and enteroviral 3C<sup>pro</sup> specificity provides a framework for the development of broad-spectrum antiviral compounds.</ArticleTitle><Pagination><StartPage>e5139</StartPage><MedlinePgn>e5139</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e5139</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/pro.5139</ELocationID><Abstract><AbstractText>The main protease from coronaviruses and the 3C protease from enteroviruses play a crucial role in processing viral polyproteins, making them attractive targets for the development of antiviral agents. In this study, we employed a combinatorial chemistry approach-HyCoSuL-to compare the substrate specificity profiles of the main and 3C proteases from alphacoronaviruses, betacoronaviruses, and enteroviruses. The obtained data demonstrate that coronavirus M<sup>pro</sup>s exhibit overlapping substrate specificity in all binding pockets, whereas the 3C<sup>pro</sup> from enterovirus displays slightly different preferences toward natural and unnatural amino acids at the P4-P2 positions. However, chemical tools such as substrates, inhibitors, and activity-based probes developed for SARS-CoV-2 M<sup>pro</sup> can be successfully applied to investigate the activity of the M<sup>pro</sup> from other coronaviruses as well as the 3C<sup>pro</sup> from enteroviruses. Our study provides a structural framework for the development of broad-spectrum antiviral compounds.</AbstractText><CopyrightInformation>© 2024 The Protein Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rut</LastName><ForeName>Wioletta</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Chemical Biology and Bioimaging, Wroclaw University of Science and Technology, Wroclaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Groborz</LastName><ForeName>Katarzyna</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Chemical Biology and Bioimaging, Wroclaw University of Science and Technology, Wroclaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Xinyuanyuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute of Molecular Medicine, University of Lübeck, Lübeck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hilgenfeld</LastName><ForeName>Rolf</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Molecular Medicine, University of Lübeck, Lübeck, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Infection Research (DZIF), Hamburg-Lübeck-Borstel-Riems Site, University of Lübeck, Lübeck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drag</LastName><ForeName>Marcin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8510-1967</Identifier><AffiliationInfo><Affiliation>Department of Chemical Biology and Bioimaging, Wroclaw University of Science and Technology, Wroclaw, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Fundacja na rzecz Nauki Polskiej</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Protein Sci</MedlineTA><NlmUniqueID>9211750</NlmUniqueID><ISSNLinking>0961-8368</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.28</RegistryNumber><NameOfSubstance UI="D000086782">Coronavirus 3C Proteases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013379" MajorTopicYN="N">Substrate Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086782" MajorTopicYN="Y">Coronavirus 3C Proteases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017934" MajorTopicYN="N">Coronavirus</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">coronaviruses</Keyword><Keyword MajorTopicYN="N">enteroviruses</Keyword><Keyword MajorTopicYN="N">substrate specificity</Keyword><Keyword MajorTopicYN="N">viral proteases</Keyword></KeywordList><CoiStatement>Wroclaw University of Science and Technology has filed a patent application covering compounds: Ac‐Abu‐Tle‐Leu‐Gln‐VS, Ac‐Abu‐DTyr‐Leu‐Gln‐VS, Biotin‐PEG(4)‐Abu‐Tle‐Leu‐Gln‐VS, and Cy5‐PEG(4)‐Abu‐Tle‐Leu‐Gln‐VS, as well as related compounds with W.R. and M.D. as inventors.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>16</Day><Hour>13</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>16</Day><Hour>13</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>16</Day><Hour>8</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39150063</ArticleId><ArticleId IdType="pmc">PMC11328108</ArticleId><ArticleId IdType="doi">10.1002/pro.5139</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anand K, Palm GJ, Mesters JR, Siddell SG, Ziebuhr J, Hilgenfeld R. Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra α‐helical domain. EMBO Journal. 2002;21(13):3213–3224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC126080</ArticleId><ArticleId IdType="pubmed">12093723</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti‐SARS drugs. Science. 2003;300(5626):1763–1767.</Citation><ArticleIdList><ArticleId IdType="pubmed">12746549</ArticleId></ArticleIdList></Reference><Reference><Citation>Boras B, Jones RM, Anson BJ, Arenson D, Aschenbrenner L, Bakowski MA, et al. Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19. Nat Commun. 2021;12(1):6055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8523698</ArticleId><ArticleId IdType="pubmed">34663813</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwer L, Moreni G, Wolthers KC, Pajkrt D. World‐wide prevalence and genotype distribution of enteroviruses. Viruses. 2021;13(3):434.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7999254</ArticleId><ArticleId IdType="pubmed">33800518</ArticleId></ArticleIdList></Reference><Reference><Citation>Carabelli AM, Peacock TP, Thorne LG, et al. SARS‐CoV‐2 variant biology: immune escape, transmission and fitness. Nature Reviews Microbiology. 2023;21(3):162–177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9847462</ArticleId><ArticleId IdType="pubmed">36653446</ArticleId></ArticleIdList></Reference><Reference><Citation>Clementz MA, Chen Z, Banach BS, Wang Y, Sun L, Ratia K, et al. Deubiquitinating and interferon antagonism activities of coronavirus papain‐like proteases. Journal of Virology. 2010;84(9):4619–4629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2863753</ArticleId><ArticleId IdType="pubmed">20181693</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai W, Zhang B, Jiang XM, et al. Structure‐based design of antiviral drug candidates targeting the SARS‐CoV‐2 main protease. Science. 2020;368(6497):1331–1335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7179937</ArticleId><ArticleId IdType="pubmed">32321856</ArticleId></ArticleIdList></Reference><Reference><Citation>Devaraj SG, Wang N, Chen Z, Chen Z, Tseng M, Barretto N, et al. Regulation of IRF‐3‐dependent innate immunity by the papain‐like protease domain of the severe acute respiratory syndrome coronavirus. Journal of Biological Chemistry. 2007;282(44):32208–32221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2756044</ArticleId><ArticleId IdType="pubmed">17761676</ArticleId></ArticleIdList></Reference><Reference><Citation>Drayman N, DeMarco JK, Jones KA, Azizi SA, Froggatt HM, Tan K, et al. Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS‐CoV‐2. Science. 2021;373(6557):931–936.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8809056</ArticleId><ArticleId IdType="pubmed">34285133</ArticleId></ArticleIdList></Reference><Reference><Citation>
European Centre for Disease Prevention and Control. Epidemiological update: echovirus 11 infections in neonates. https://www.ecdc.europa.eu/en/news-events/epidemiological-update-echovirus-11-infections-neonates. Accessed 19 Jul 2023.</Citation></Reference><Reference><Citation>Fan K, Wei P, Feng Q, Chen S, Huang C, Ma L, et al. Biosynthesis, purification, and substrate specificity of severe acute respiratory syndrome coronavirus 3C‐like proteinase. Journal of Biological Chemistry. 2004;279(3):1637–1642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7980035</ArticleId><ArticleId IdType="pubmed">14561748</ArticleId></ArticleIdList></Reference><Reference><Citation>Frieman M, Ratia K, Johnston RE, Mesecar AD, Baric RS. Severe acute respiratory syndrome coronavirus papain‐like protease ubiquitin‐like domain and catalytic domain regulate antagonism of IRF3 and NF‐kappaB signaling. Journal of Virology. 2009;83(13):6689–6705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2698564</ArticleId><ArticleId IdType="pubmed">19369340</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung TS, Liu DX. Similarities and dissimilarities of COVID‐19 and other coronavirus diseases. Annual Review of Microbiology. 2021;75:19–47.</Citation><ArticleIdList><ArticleId IdType="pubmed">33492978</ArticleId></ArticleIdList></Reference><Reference><Citation>Göhl M, Zhang L, el Kilani H, Sun X, Zhang K, Brönstrup M, et al. From repurposing to redesign: optimization of boceprevir to highly potent inhibitors of the SARS‐CoV‐2 Main protease. Molecules. 2022;27(13):4292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9268446</ArticleId><ArticleId IdType="pubmed">35807537</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamre D, Procknow JJ. A new virus isolated from the human respiratory tract. Proceedings of the Society for Experimental Biology and Medicine. 1966;121(1):190–193.</Citation><ArticleIdList><ArticleId IdType="pubmed">4285768</ArticleId></ArticleIdList></Reference><Reference><Citation>Hegyi A, Ziebuhr J. Conservation of substrate specificities among coronavirus main proteases. Journal of General Virology. 2002;83:595–599.</Citation><ArticleIdList><ArticleId IdType="pubmed">11842254</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilgenfeld R. From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS Journal. 2014;281(18):4085–4096.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7163996</ArticleId><ArticleId IdType="pubmed">25039866</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Z, du X, Xu Y, Deng Y, Liu M, Zhao Y, et al. Structure of M(pro) from SARS‐CoV‐2 and discovery of its inhibitors. Nature. 2020;582(7811):289–293.</Citation><ArticleIdList><ArticleId IdType="pubmed">32272481</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawashima S, Matsui Y, Adachi T, Morikawa Y, Inoue K, Takebayashi S, et al. Ensitrelvir is effective against SARS‐CoV‐2 3CL protease mutants circulating globally. Biochemical and Biophysical Research Communications. 2023;645:132–136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839456</ArticleId><ArticleId IdType="pubmed">36689809</ArticleId></ArticleIdList></Reference><Reference><Citation>Kesheh MM, Hosseini P, Soltani S, Zandi M. An overview on the seven pathogenic human coronaviruses. Review in Medical Virology. 2022;32(2):e2282.</Citation><ArticleIdList><ArticleId IdType="pubmed">34339073</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamura N, Sacco MD, Ma C, Hu Y, Townsend JA, Meng X, et al. Expedited approach toward the rational Design of Noncovalent SARS‐CoV‐2 Main protease inhibitors. Journal of Medicinal Chemistry. 2022;65(4):2848–2865.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8536799</ArticleId><ArticleId IdType="pubmed">33891389</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei J, Hilgenfeld R. RNA‐virus proteases counteracting host innate immunity. FEBS Letters. 2017;591(20):3190–3210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7163997</ArticleId><ArticleId IdType="pubmed">28850669</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Hilgenfeld R, Whitley R, de Clercq E. Therapeutic strategies for COVID‐19: progress and lessons learned. Nature Reviews Drug Discovery. 2023;22(6):449–475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10113999</ArticleId><ArticleId IdType="pubmed">37076602</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Lin C, Zhou X, Zhong F, Zeng P, Yang Y, et al. Structural basis of the Main proteases of coronavirus bound to drug candidate PF‐07321332. J Virol. 2022;96(8):e0201321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9044943</ArticleId><ArticleId IdType="pubmed">35389231</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin C, Jiang H, Li W, Zeng P, Zhou X, Zhang J, et al. Structural basis for the inhibition of coronaviral main proteases by ensitrelvir. Structure. 2023;31(9):1016–1024 e3.</Citation><ArticleIdList><ArticleId IdType="pubmed">37421945</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma C, Sacco MD, Hurst B, Townsend JA, Hu Y, Szeto T, et al. Boceprevir, GC‐376, and calpain inhibitors II, XII inhibit SARS‐CoV‐2 viral replication by targeting the viral main protease. Cell Research. 2020;30(8):678–692.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7294525</ArticleId><ArticleId IdType="pubmed">32541865</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy MW. Ensitrelvir as a potential treatment for COVID‐19. Expert Opinion on Pharmacotherapy. 2022;23(18):1995–1998.</Citation><ArticleIdList><ArticleId IdType="pubmed">36350029</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee A, Morosky SA, Delorme‐Axford E, Dybdahl‐Sissoko N, Oberste MS, Wang T, et al. The coxsackievirus B 3C protease cleaves MAVS and TRIF to attenuate host type I interferon and apoptotic signaling. PLOS Pathogens. 2011;7(3):e1001311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059221</ArticleId><ArticleId IdType="pubmed">21436888</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen DR, Allerton CMN, Anderson AS, Aschenbrenner L, Avery M, Berritt S, et al. An oral SARS‐CoV‐2 M(pro) inhibitor clinical candidate for the treatment of COVID‐19. Science. 2021;374(6575):1586–1593.</Citation><ArticleIdList><ArticleId IdType="pubmed">34726479</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SW, Pons‐Salort M, Messacar K, Cook C, Meyers L, Farrar J, et al. Epidemiological dynamics of enterovirus D68 in the United States and implications for acute flaccid myelitis. Science Translational Medicine. 2021;13(584).</Citation><ArticleIdList><ArticleId IdType="pubmed">33692131</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons‐Salort M, Oberste MS, Pallansch MA, Abedi GR, Takahashi S, Grenfell BT, et al. The seasonality of nonpolio enteroviruses in the United States: patterns and drivers. Proceedings of the National Academy of Sciences of the U SA. 2018;115(12):3078–3083.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5866597</ArticleId><ArticleId IdType="pubmed">29507246</ArticleId></ArticleIdList></Reference><Reference><Citation>Rut W, Groborz K, Zhang L, Sun X, Zmudzinski M, Pawlik B, et al. SARS‐CoV‐2 M(pro) inhibitors and activity‐based probes for patient‐sample imaging. Nature Chemical Biology. 2021;17(2):222–228.</Citation><ArticleIdList><ArticleId IdType="pubmed">33093684</ArticleId></ArticleIdList></Reference><Reference><Citation>Steuber H, Hilgenfeld R. Recent advances in targeting viral proteases for the discovery of novel antivirals. Current Topics in Medicinal Chemistry. 2010;10(3):323–345.</Citation><ArticleIdList><ArticleId IdType="pubmed">20166951</ArticleId></ArticleIdList></Reference><Reference><Citation>Unoh Y, Uehara S, Nakahara K, Nobori H, Yamatsu Y, Yamamoto S, et al. Discovery of S‐217622, a noncovalent Oral SARS‐CoV‐2 3CL protease inhibitor clinical candidate for treating COVID‐19. Journal of Medicinal Chemistry. 2022;65(9):6499–6512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8982737</ArticleId><ArticleId IdType="pubmed">35352927</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Hoek L, Pyrc K, Jebbink MF, Vermeulen‐Oost W, Berkhout RJM, Wolthers KC, et al. Identification of a new human coronavirus. Nature Medicine. 2004;10(4):368–373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095789</ArticleId><ArticleId IdType="pubmed">15034574</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F, Chen C, Tan W, Yang K, Yang H. Structure of Main protease from human coronavirus NL63: insights for wide Spectrum anti‐coronavirus drug design. Scientific Reports. 2016;6:22677.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4780191</ArticleId><ArticleId IdType="pubmed">26948040</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo PC, Lau SK, Chu CM, et al. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. Journal of Virology. 2005;79(2):884–895.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC538593</ArticleId><ArticleId IdType="pubmed">15613317</ArticleId></ArticleIdList></Reference><Reference><Citation>Zephyr J, Kurt Yilmaz N, Schiffer CA. Viral proteases: structure, mechanism and inhibition. Enzyme. 2021;50:301–333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8595904</ArticleId><ArticleId IdType="pubmed">34861941</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Lin D, Sun X, et al. Crystal structure of SARS‐CoV‐2 main protease provides a basis for design of improved α‐ketoamide inhibitors. Science. 2020a;368(6489):409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164518</ArticleId><ArticleId IdType="pubmed">32198291</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Lin D, Kusov Y, et al. α‐Ketoamides as broad‐Spectrum inhibitors of coronavirus and enterovirus replication: structure‐based design, synthesis, and activity assessment. Journal of Medicinal Chemistry. 2020b;63(9):4562–4578.</Citation><ArticleIdList><ArticleId IdType="pubmed">32045235</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Fang C, Zhang Q, Zhang R, Zhao X, Duan Y, et al. Crystal structure of SARS‐CoV‐2 main protease in complex with protease inhibitor PF‐07321332. Protein Cell. 2022;13(9):689–693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8533666</ArticleId><ArticleId IdType="pubmed">34687004</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>